All News
Filter News
Found 251 articles
-
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
11/9/2023
Sana Biotechnology, Inc. (NASDAQ: SANA) today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC291 in patients with multiple B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
-
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
11/8/2023
Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, reported financial results and business highlights for the third quarter 2023.
-
BioSpace has published its annual 2024 Best Places to Work list.
-
BioSpace Announces 2024 Best Places to Work in Biopharma Winners
11/7/2023
BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.
-
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
11/2/2023
Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.
-
The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023.
-
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
10/10/2023
Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced a portfolio update, including both increased focus on its ex vivo cell therapy product candidates and an IND submission for SC291 in autoimmune diseases.
-
ProFound Therapeutics Expands Leadership Team With Appointment of Klaus Urbahns as Chief Scientific Officer
9/25/2023
ProFound™ Therapeutics today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer.
-
Sana Biotechnology to Present at September 2023 Investor Conferences
8/30/2023
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.
-
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
8/15/2023
Alltrna, a Flagship Pioneering company unlocking transfer RNA biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, announced that it has appointed Chris Henderson, Ph.D., as Chief Scientific Officer and promoted William Kiesman, Ph.D., to Chief Technology Officer.
-
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
8/3/2023
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the second quarter 2023.
-
With its hypoimmune technology, the company looks to reshape the future of cell and gene therapy.
-
Senda Biosciences Appoints Igor Matushansky as Chief Medical Officer
7/24/2023
Senda Biosciences, Inc. today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.
-
Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.
7/24/2023
Specific Biologics Inc., a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D. to its scientific advisory board.
-
APIE Therapeutics Appoints Ashwin Datt Chief Executive OfficerFormer CEO and Founder, Esther Alegria Remains on Executive Team Focused on Driving Research & Development Through External Collaborations
7/11/2023
APIE Therapeutics (APIE Tx) , a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin Datt as CEO and a member of its Board of Directors.
-
ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential
6/21/2023
ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds.
-
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
6/16/2023
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data from six presentations, including two oral presentations, at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting.
-
Arvinas Announces Changes to its Board of Directors - June 15, 2023
6/15/2023
Arvinas, Inc. announced that Timothy Shannon, M.D., current Chairperson and a member of the company’s Board of Directors since 2013, has stepped down from this role.
-
Ring Therapeutics Announces Appointment of Bioprocess and Biomanufacturing Veteran Konstantin Konstantinov, Ph.D. as Chief Technology Officer
6/7/2023
Ring Therapeutics today announced the appointment of Konstantin Konstantinov, Ph.D., as its Chief Technology Officer to lead the research and development teams and optimize the process and strategy to support clinical advancement of its Anellogy platform.
-
Cellarity Appoints Dr. Gregory J. Moore to Board of Directors
6/6/2023
Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company’s Board of Directors.